Copiktra
Drug
Verastem, Inc.
Total Payments
$5.6M
Transactions
5,155
Doctors
1,635
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $22,700 | 8 | 0 |
| 2020 | $2.4M | 1,447 | 458 |
| 2019 | $3.2M | 3,700 | 1,422 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.9M | 1,688 | 70.2% |
| Consulting Fee | $922,015 | 172 | 16.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $536,138 | 144 | 9.6% |
| Travel and Lodging | $105,802 | 410 | 1.9% |
| Food and Beverage | $77,596 | 2,717 | 1.4% |
| Space rental or facility fees (teaching hospital only) | $27,353 | 23 | 0.5% |
| Grant | $5,000 | 1 | 0.1% |
Payments by Type
Research
$3.9M
1,688 transactions
General
$1.7M
3,467 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) | Verastem, Inc. | $613,110 | 1 |
| VS-0145-225 | Verastem, Inc. | $567,145 | 2 |
| The Combination of Duvelisib, a PI3K?,? Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts | Verastem, Inc. | $334,667 | 0 |
| VS-0145-229 | Verastem, Inc. | $322,277 | 0 |
| IST-145-06 | Verastem, Inc. | $253,431 | 0 |
| A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study | Verastem, Inc. | $239,672 | 0 |
| VS-0145-225 | Secura Bio, Inc. | $169,992 | 1 |
| IST-145-015 | Verastem, Inc. | $135,953 | 0 |
| 18-089 A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome | Verastem, Inc. | $122,400 | 0 |
| IPI-145 | Verastem, Inc. | $107,725 | 0 |
| OSU-18173 | Verastem, Inc. | $93,919 | 0 |
| VS-145-130 | Secura Bio, Inc. | $92,458 | 0 |
| GCNCR1029 - A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) | Verastem, Inc. | $84,066 | 0 |
| 145-23 (Rollover) | Verastem, Inc. | $66,182 | 0 |
| A Pre-Clinical In Vitro and In Vivo Study of the Inhibitor of Phosphoinositide-3-Kinase (PI3K)-Delta and -Gamma Duvelisib to Overcome Therapeutically Resistant MCL | Verastem, Inc. | $65,800 | 0 |
| VS-0145-130 | Verastem, Inc. | $65,547 | 0 |
| A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With DuvelisibIPI-145-23 | Verastem, Inc. | $62,099 | 0 |
| VS-0145-229 | Secura Bio, Inc. | $59,573 | 0 |
| A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO) | Verastem, Inc. | $56,355 | 4 |
| VRSTM - Duvelisib | Verastem, Inc. | $50,000 | 0 |
Top Doctors Receiving Payments for Copiktra
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Milwaukee, WI | $4.0M | 1,754 |
| Elenie Bartzokis | — | Celebration, FL | $221,325 | 13 |
| , M.D | Internal Medicine | Jamaica Plain, MA | $205,520 | 9 |
| , MD | Medical Oncology | Fort Worth, TX | $85,133 | 102 |
| , MD | Hematology & Oncology | Los Angeles, CA | $78,849 | 73 |
| , MD | Internal Medicine | Milwaukee, WI | $51,032 | 61 |
| , M.D | Hematology & Oncology | Phoenix, AZ | $38,624 | 30 |
| , MD | Medical Oncology | Baltimore, MD | $30,248 | 19 |
| , M.D | Hematology & Oncology | Tempe, AZ | $26,982 | 20 |
| , M.D | Internal Medicine | Portland, OR | $20,971 | 10 |
| , M.D | Hematology & Oncology | Brooklyn, NY | $19,449 | 33 |
| , MD | Internal Medicine | Charlotte, NC | $18,600 | 20 |
| , M.D | Hematology & Oncology | Washington, DC | $17,531 | 7 |
| , MD | Hematology & Oncology | Orlando, FL | $16,521 | 18 |
| , M.D | Hematology & Oncology | Boston, MA | $15,950 | 13 |
| , MD | Hematology & Oncology | Dallas, TX | $15,439 | 14 |
| , MD | Medical Oncology | Dallas, TX | $14,615 | 10 |
| , M.D | Medical Oncology | San Francisco, CA | $13,614 | 6 |
| , MD | Hematology & Oncology | Seattle, WA | $13,388 | 7 |
| , MD PHD | Hematology & Oncology | Seattle, WA | $13,357 | 18 |
| , M.D | Internal Medicine | Cleveland, OH | $12,617 | 9 |
| , MD | Medical Oncology | Sparta, NJ | $12,500 | 1 |
| , MD | Hematology & Oncology | Binghamton, NY | $12,285 | 14 |
| , M.D | Hematology | Atlanta, GA | $11,845 | 8 |
| , M.D | Hematology & Oncology | Boston, MA | $11,827 | 6 |
Ad
Manufacturing Companies
- Verastem, Inc. $5.3M
- Secura Bio, Inc. $340,402
Product Information
- Type Drug
- Total Payments $5.6M
- Total Doctors 1,635
- Transactions 5,155
About Copiktra
Copiktra is a drug associated with $5.6M in payments to 1,635 healthcare providers, recorded across 5,155 transactions in the CMS Open Payments database. The primary manufacturer is Verastem, Inc..
Payment data is available from 2019 to 2022. In 2022, $22,700 was paid across 8 transactions to 0 doctors.
The most common payment nature for Copiktra is "Unspecified" ($3.9M, 70.2% of total).
Copiktra is associated with 20 research studies, including "A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)" ($613,110).